Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialDomenico Russo, Cyrus Badshah, Toshiro Kawakita et al.|The Lancet Haematology|2023Cited by 100
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).Michael Platten, Wolfgang Wick, Daniela Schilling et al.|Journal of Clinical Oncology|2018Cited by 25